Dr. Rizvi on Biomarkers of Response to Immunotherapy in NSCLC

EP: 1.Dr. Giaccone on Treatment Options in NSCLC

Now Viewing

EP: 2.Dr. Rizvi on Biomarkers of Response to Immunotherapy in NSCLC

EP: 3.Dr. West on the Use of Nivolumab/Ipilimumab in Metastatic NSCLC

EP: 4.Dr. Gandara on the Benefit of Nivolumab/Ipilimumab Plus Chemo in Metastatic NSCLC

EP: 5.Dr. Rizvi on the Implications of the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLC

EP: 6.Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLC

EP: 7.Dr. Raez on the Impact of PD-L1 Status on Immunotherapy Outcomes in NSCLC

EP: 8.Dr. Garon on Immunotherapy Treatment Considerations in NSCLC

EP: 9.The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer

Naiyer A. Rizvi, MD, Price Family ​Professor of ​Medicine; director of Thoracic Oncology; and co-director of Cancer Immunotherapy at Herbert Irving Comprehensive Cancer Center, of Columbia University Medical Center, as well as the research director at the Price Family Comprehensive Center for Chest Care of NewYork-Presbyterian Hospital, discusses the use of biomarkers to select patients with non–small cell lung cancer (NSCLC) for treatment with immunotherapy.

Tumor mutational burden (TMB) can be a useful tool to select patients with NSCLC who should receive immunotherapy, according to Rizvi. Pembrolizumab (Keytruda) monotherapy, for example, was approved by the FDA in June 2020 for patients with unresectable or metastatic solid tumors with a high TMB of 10 mutations per megabase or higher who have progressed after previous therapy and who have no satisfactory available therapeutic options. There is also some interest in trying to identify patients with NSCLC who are positive for both PD-L1 expression and TMB, as this subset may be more likely to respond to PD-1 monotherapy, explains Rizvi.

Patients who have a PD-L1 expression of 50% or higher are generally treated with pembrolizumab monotherapy, although retrospective data with the agent and additional data with cemiplimab (Libtayo) indicate that different PD-L1 levels can impact response to treatment. For example, patients with a PD-L1 expression of 90% or higher are more likely to benefit from a PD-1 monotherapy versus someone with a PD-L1 expression of 50% to 60%, according to Rizvi.

Additionally, mutations in STK11 and KEAP1 are most commonly observed in these patients and they have been shown to be associated with poor prognosis and potential resistance to immunotherapy, adds Rizvi. Some approaches may help to actively address these specific mutations, such as epigenetic modifiers, concludes Rizvi.